The Walter Hubert Lecture
1997

Signalling Pathways and Targets for Cancer Therapy

publication Evidence: moderate

Author Information

Author(s): C J Marshall, A. Wittinghofer, N. Nassarl, G. Horn, M. Geyer, H.R. Kalbitzee, C. Herrmann, Nicholas B. Lydon, Elisabeth Buchdunger, Helmut Mett, Marcel Muller, Robert Cozens, David Stover, Pascal Furet, Peter Traxler, J. Gibbs, A. Burkhardt, C. Buser, D. Heimbrook, K. Koblan, N. Kohl, R. Lobell, C. Omer, T. Williams, R. Barrington, J. J. Windle, R. Mangues, A. Pellicer, S. Graham, G. Hartman, A. Oliff, Robert C. Jackson, I. Judson, Ann L Jackman, Hilary Calvert, J. Carmichael, R.A. Laskey, G. Milano, lo Milner, Gerard I. Evan, Laurent MEIJER, E.Kenneth Parkinson, VG Brunton, C Paraskeva, MC Frame

Primary Institution: Institute of Cancer Research

Hypothesis

Ras proteins and their downstream signalling pathways are potential targets for cancer therapy.

Conclusion

Ras signalling pathways are essential for the proliferation of certain cancer cells, making them attractive targets for therapeutic intervention.

Supporting Evidence

  • Ras proteins are mutated in many human tumors, leading to uncontrolled cell growth.
  • Farnesyltransferase inhibitors can block the function of Ras proteins.
  • Raf/MAP kinase pathway is essential for the transformation of cells with Ras oncogenes.
  • Small molecule inhibitors targeting Ras signalling pathways may be effective in cancer treatment.

Takeaway

Ras proteins help cancer cells grow, and by blocking their signals, we might stop the cancer from spreading.

Methodology

The study discusses various approaches to inhibit Ras proteins and their signalling pathways, including the use of farnesyltransferase inhibitors and retroviral vectors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication